This podcast episode provides a comprehensive overview of the FDA drug development process for cannabinoid and psychedelic therapeutics. The hosts discuss the journey from pre-clinical research through post-marketing surveillance, explaining key stages including:

- Pre-clinical research and molecular interactions with brain receptors

- The IND (Investigational New Drug) application process

- The three phases of clinical trials and their purposes

- Special challenges related to Schedule I substances and regulatory hurdles

The conversation also explores broader implications for mental health treatment and addiction, emphasizing how these emerging therapies could reshape our understanding of healing and consciousness.